Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study.
Author | |
---|---|
Abstract | :
Ventolin Nebules® (reference product; GlaxoSmithKline) was the first licensed nebulizer solution containing the rapid-onset, short-acting β2-agonist salbutamol. Salbutamol Steri-Neb™ (comparator; Teva Pharmaceuticals, Inc.) has the same chemical composition as the reference product. This study evaluated whether the effectiveness of the comparator is non-inferior to the reference product alongside concomitant medications during real-life clinical management of COPD exacerbations. Safety in terms of adverse events (AEs) was also examined. |
Year of Publication | :
0
|
Journal | :
PloS one
|
Volume | :
13
|
Issue | :
1
|
Number of Pages | :
e0191404
|
Date Published | :
2018
|
URL | :
http://dx.plos.org/10.1371/journal.pone.0191404
|
DOI | :
10.1371/journal.pone.0191404
|
Short Title | :
PLoS One
|
Download citation |